New publication on crovalimab’s pharmacokinetics and exposure–response in PNH trials

The findings demonstrate that crovalimab achieves complete terminal complement activity inhibition, provides effective disease control, and maintains a safety profile comparable to existing C5 inhibitors. Notably, the study also highlights crovalimab’s potential to reduce treatment burden, offering a promising avenue for improving care in PNH.